Delft: Aragen Bioscience and Getinge announced the successful validation of latter’s single-use production reactors (SUPR) for large-scale recombinant antibody production. This collaboration combines Aragen’s expertise in biopharmaceutical manufacturing and Getinge’s innovative single-use technology, enabling seamless production of large-scale batches.
The validation study was conducted at Aragen’s state-of-the-art R&D facility in Morgan Hill, California. It demonstrated the SUPR bioreactor‘s exceptional performance in generating high-quality recombinant antibodies. The reactor is designed to be a single-use alternative to traditional stainless-steel bioreactors at the pilot and production scale. This allows the upstream process to continue from research to production with one trusted single-use platform. R&D and process optimisation performed in the AppliFlex ST or Applikon Bio can now be easily scaled up using the SUPR.
Dr Subodh Deshmukh, CEO, Aragen Bioscience, said, “Getinge’s 50L and 250L single-use bioreactor platforms are now available at Aragen to support the growing demand for large-scale recombinant antibody production.”
Timo Walvoort, Director, Research & Development, Getinge said, “Through closely working together, we have developed the world’s first single-use true bioreactor, with unparalleled ease-of-use. I look forward to many more fruitful collaborations with our friends at Aragen!”
Ease of scaleup, from 2 Ltr to 50 Ltr to 250 Ltr, is one of the most challenging aspects of bioproduction. Aragen scientists used their proprietary platform process to run in the SUPR system and achieved excellent results. Critical parameters, such as cell growth pattern, metabolites, osmolality, pH and production yield profiles remained steady throughout the scaleup.
